Biopharmaceuticals Are Shaping the Future of Modern Healthcare; India Well-Positioned to Emerge as a Global Leader : Smt. Anupriya Patel

1. At a Glance

• Statement by Smt. Anupriya Patel, MoS Chemicals & Fertilizers, at 2nd ASSOCHAM Pharma Summit & Awards 2026, positioning India as an emerging global biopharma hub [S1].
• Biopharma SHAKTI (Strategy for Healthcare Advancement through Knowledge, Technology and Innovation) — flagship scheme announced in Union Budget 2026-27 with target of 100 biologics by 2047 [S1][S5][S6].
• Examinable for Prelims (scheme nomenclature, outlay, ministry) and Mains GS-III (Sci-Tech, indigenisation, manufacturing, IPR).

2. Why in the News

• 11 June 2026: MoS Anupriya Patel addressed the 2nd Pharma Summit & Awards 2026 (ASSOCHAM), reiterating Biopharma SHAKTI's 100-biologics-by-2047 target and urged industry to scale biologics and biosimilars capabilities [S1].
• Follows Budget 2026-27 announcement of Biopharma SHAKTI by FM and subsequent push by Dr. Jitendra Singh (MoS S&T) [S5][S6].

3. Background & Evolution

• 2020: PLI Scheme for Bulk Drugs / KSMs / APIs notified (outlay ₹6,940 cr; FY2022-23 to FY2028-29) to cut import dependence on 41 critical APIs [S4].
• 2020: Bulk Drug Parks scheme — 3 Greenfield parks approved [S2][S4].
• 2021: PLI for Pharmaceuticals (₹15,000 cr) covering biopharmaceuticals, complex generics, patented drugs [S2].
• Feb 2026: Union Budget 2026-27 proposes Biopharma SHAKTI with ₹10,000 cr outlay over 5 years [S2][S5].
• April 2026: 9th India Pharma 2026 Conference held in New Delhi (13-14 April), theme "Discover in India: Leapfrogging Life-Sciences Innovation" [S3].
• June 2026: ASSOCHAM Pharma Summit — MoS Patel articulates 100 biologics by 2047 vision aligned with Viksit Bharat 2047 [S1].

4. Core Static Facts

• Scheme: Biopharma SHAKTI = Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S5].
• Implementing Ministry: Ministry of Chemicals & Fertilizers — Department of Pharmaceuticals (DoP) [S1][S2].
• Outlay: ₹10,000 crore over 5 years [S2][S5].
• Target: Launch 100 biologics by 2047; capture 5% of global biopharmaceutical market [S1][S2].
• Pillars: Biopharma Discovery Grant & Equity Fund; Biopharma-focused NIPER Network + National Biopharma R&D Network; India Clinical Trial Sites Network (1,000 accredited sites); Fermentation-based Bulk Drugs & Building Blocks Manufacturing Incentive; Biosimilars & Emerging Biologics Manufacturing Initiative [S2].
• Regulatory arm: CDSCO to be strengthened with a dedicated Scientific Review Cadre including specialists for gene therapy [S2].
• Pharmaceutical market size: USD 50 billion (FY2023-24) — domestic USD 23.5 bn + exports USD 26.5 bn; projected USD 130 billion by 2030 [S4].
• Global standing: India = largest provider of generic medicines by volume, 20% of global generic supply [S4].

5. Multi-Dimensional Analysis

Economic - ₹10,000 cr outlay; aims to convert generics dominance into value-added biologics & biosimilars revenue [S2][S4]. - Reduces import dependence on KSMs/APIs (complemented by ₹6,940 cr PLI Bulk Drugs scheme — 48 projects approved, 34 commissioned by Dec 2024) [S4].

Scientific / Technological - Funds discovery + development equity, supporting startups in mAbs, gene therapy, cell therapy [S2]. - Builds 1,000-site clinical trial network for Phase I-III global-grade trials [S2].

Administrative / Regulatory - CDSCO Scientific Review Cadre — fixes long-standing reviewer-shortage bottleneck [S2]. - Coordination across DoP, DBT, DSIR, ICMR; NIPERs anchor R&D translation [S2].

Social / Health - Biosimilars lower cost of cancer, autoimmune therapies — improves access [S2]. - Aligns with Viksit Bharat 2047 healthcare equity goals [S1].

Geopolitical / Strategic - "Pharmacy of the World" branding extended to high-end biologics; reduces dependence on Western originators [S4]. - Counter-balances China's API dominance via fermentation-based bulk-drug push [S2].

6. Recent Developments (last 12-18 months)

• Feb 2026: Biopharma SHAKTI announced in Union Budget 2026-27 [S5][S6].
• April 13-14, 2026: India Pharma 2026 (9th edition) in New Delhi [S3].
• 11 June 2026: ASSOCHAM Pharma Summit — MoS Patel reaffirms 100 biologics by 2047 [S1].
• DHR's Medical Colleges Research Connect 2026 — ₹4,800 cr DHR allocation flagged for biomedical research [S3].

7. Prelims Hooks

• Biopharma SHAKTI full form: Strategy for Healthcare Advancement through Knowledge, Technology and Innovation [S5].
• Outlay: ₹10,000 crore / 5 years [S2].
• Goal: 100 biologics by 2047 [S1].
• Target: 5% of global biopharma market share [S2].
• Announced in Union Budget 2026-27 [S5].
• Implementing Department: Department of Pharmaceuticals under Min. of Chemicals & Fertilizers (NOT MoHFW, NOT DBT) [S1].
• Clinical Trial Network target: 1,000 accredited sites [S2].
• Regulator strengthened: CDSCO via new Scientific Review Cadre [S2].
• PLI Bulk Drugs outlay: ₹6,940 cr; tenure FY2022-23 to FY2028-29; covers 41 APIs [S4].
• PLI Bulk Drugs: 48 projects approved, 34 commissioned for 25 bulk drugs (Dec 2024) [S4].
• India's pharma market FY2023-24: USD 50 bn (exports USD 26.5 bn) [S4].
• Projected pharma market by 2030: USD 130 bn [S4].
• India's share in global generics by volume: 20% [S4].
• India Pharma 2026 theme: "Discover in India: Leapfrogging Life-Sciences Innovation" [S3].

8. Mains Relevance

• GS-III — Science & Technology (indigenisation, biotech); Indian Economy (manufacturing, PLI); Achievements of Indians in S&T.
• GS-II — Health (access to medicines, regulation).
• Probable stems: 1. "Discuss how Biopharma SHAKTI can transition India from a 'pharmacy of generics' to a 'biologics innovator'. What regulatory and R&D bottlenecks must be addressed?" 2. "Examine the role of PLI schemes (Bulk Drugs, Pharma, Biopharma SHAKTI) in reducing India's strategic import dependence in pharmaceuticals." 3. "Biologics and biosimilars hold the key to affordable advanced therapies. Critically evaluate India's preparedness."

9. Related Topics to Study Next

• PLI Scheme for Bulk Drugs / APIs — direct upstream complement.
• National Biopharma Mission (BIRAC/DBT) — earlier ₹1,500 cr biopharma R&D effort.
• CDSCO & New Drugs and Clinical Trials Rules, 2019 — regulatory framework for biologics.
• NIPERs (National Institutes of Pharmaceutical Education & Research) — R&D anchors of SHAKTI.
• Bulk Drug Parks Scheme — feedstock infrastructure.
• TRIPS & Patents (Amendment) Act 2005 — IPR backdrop for biosimilars.
• Jan Aushadhi (PMBJP) — affordability angle.
• Genome India / BioE3 Policy (2024) — converging biotech industrial policy.

10. Common Errors / Trap Areas

• Biopharma SHAKTI is under DoP / Min. of Chemicals & Fertilizers, NOT DBT or MoHFW.
• Outlay is ₹10,000 cr (Biopharma SHAKTI) — do not confuse with ₹6,940 cr (PLI Bulk Drugs) or ₹15,000 cr (PLI Pharma).
• 100 biologics by 2047 (not 100 biosimilars; biologics is broader incl. mAbs, vaccines, gene therapy).
• "5% global market share" target is for biopharma, while India already holds 20% of global generics by volume — different denominators.
• Biopharma SHAKTI was announced in Budget 2026-27, not 2024 or 2025.

11. Sources

• [S1] Press Release Page — PIB (Anupriya Patel, ASSOCHAM Pharma Summit) — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2271807 — (tier: 1)
• [S2] Bio Pharma SHAKTI scheme — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2237416&reg=3&lang=1 — (tier: 1)
• [S3] India Pharma 2026 / 9th India Pharma Conference — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2251112&reg=3&lang=1 — (tier: 1)
• [S4] Transforming India into a Global Biopharma Hub / India's Pharmaceuticals in Global Healthcare — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2222079&reg=3&lang=2 — (tier: 1)
• [S5] Biopharma SHAKTI proposed in Union Budget 2026-27 — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221443&reg=3&lang=2 — (tier: 1)
• [S6] Budget 2026-27 announcement of Biopharma Shakti (Dr. Jitendra Singh) — PIB — https://www.pib.gov.in/PressReleasePage.aspx?PRID=2221778&reg=3&lang=2 — (tier: 1)